<p>Renvela is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:</p><ul><li>adult patients on dialysis (a technique to remove unwanted substances from the blood);</li><li>adults and children from 6 years of age with chronic (long term) kidney disease.</li></ul><p>Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease. It contains the active substance sevelamer carbonate.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.</p> <p>Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.</p> <p>Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D<sub>3</sub> or one of its analogues to control the development of renal bone disease.</p> </div>
Therapeutic Area (MeSH)
ATC Code
V03AE02
ATC Item
N/A
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sevelamer carbonate | N/A | sevelamer carbonate |
EMA Name
Renvela
Medicine Name
Renvela
Aliases
N/ANo risk management plan link.
